Cetylpyridinium

Summary

Cetylpyridinium (CHEMBL305906) is an approved small molecule (ATC D09AA07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D09AA07 (+3 more)
• Clinical trials: 21
• Chemistry: 304.5 Da · C21H38N+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL305906
Name	Cetylpyridinium
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	2683
ChEBI	CHEBI:32914
ATC	D09AA07, B05CA01, D08AJ03, R02AA06
Molecular formula	C21H38N+
Molecular weight	304.5
InChIKey	NEUSVAOJNUQRTM-UHFFFAOYSA-N

SMILES: CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1

IUPAC name: 1-hexadecylpyridin-1-ium

Also known as: Cetylpyridinium, SID124890337, CETYLPYRIDINIUM, CETYLPYRIDINIUM CHLORIDE, cetylpyridinium

Parent form; salt/anhydrous children: CHEMBL34833, CHEMBL334255, CHEMBL1710321, CHEMBL2003538

Patent coverage: 4,448 distinct patent families (10,261 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: Alpha-2A adrenergic receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Sodium channel protein type 5 subunit alpha, D(1A) dopamine receptor, Estrogen receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 18 potent at pChembl ≥ 5 of 26 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	6.26	AC50	545.7	nM	CHEMBL_ACT_25194289
Q01827	6.14	AC50	730	nM	CHEMBL_ACT_25197340
CHRM2	6.08	AC50	826.7	nM	CHEMBL_ACT_25195498
KCNH2	5.89	AC50	1300	nM	CHEMBL_ACT_25117202
SLC6A2	5.64	AC50	2308	nM	CHEMBL_ACT_25145762
SLC6A3	5.62	AC50	2404	nM	CHEMBL_ACT_25124721
PTGS1	5.61	AC50	2464	nM	CHEMBL_ACT_25205919
SLC6A4	5.53	AC50	2960	nM	CHEMBL_ACT_25151089
ADORA3	5.49	AC50	3264	nM	CHEMBL_ACT_25198527
TBXA2R	5.47	AC50	3359	nM	CHEMBL_ACT_25197624
PGR	5.34	AC50	4539	nM	CHEMBL_ACT_25204053
ACHE	5.33	AC50	4678	nM	CHEMBL_ACT_25142310
DRD1	5.32	AC50	4837	nM	CHEMBL_ACT_25114972
OPRM1	5.29	AC50	5089	nM	CHEMBL_ACT_25157937
ADRA2A	5.21	AC50	6094	nM	CHEMBL_ACT_25156191
ADRA1A	5.19	AC50	6426	nM	CHEMBL_ACT_25218646
PTGS1	5.13	AC50	7455	nM	CHEMBL_ACT_25204986
HTR1A	5.01	AC50	9868	nM	CHEMBL_ACT_25164786

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE3	8
PHASE4	6
EARLY_PHASE1	2
Not specified	2
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02360995	PHASE4	COMPLETED	The Clinical Investigation of Toothpaste as Compared to Toothpaste and Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US
NCT02366689	PHASE4	COMPLETED	Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)
NCT03179735	PHASE4	UNKNOWN	Mouthwashes During Orthodontic Treatment
NCT03219840	PHASE4	COMPLETED	Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis
NCT05802628	PHASE4	COMPLETED	Salivary Drug Concentration Exploratory Study of Cetylpyridinium Chloride Buccal Tablets
NCT07211061	PHASE4	COMPLETED	A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods
NCT00687037	PHASE3	COMPLETED	Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power
NCT00729599	PHASE3	COMPLETED	Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.
NCT02193165	PHASE3	COMPLETED	The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis
NCT02756377	PHASE2/PHASE3	COMPLETED	A Comparison of Mouth Rinse Containing Alcohol-free Chlorhexidine With a Cetylpyridinium Chloride in Periodontal Diseases
NCT06479226	PHASE3	COMPLETED	Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses
NCT06607172	PHASE3	COMPLETED	Clinical Efficacy of the Combined Effect of Oral Irrigator and Chemicals (0.075% CPC)
NCT06770114	PHASE3	COMPLETED	Clinical Study to Investigate a New Mouthwash in Reducing Plaque and Helping Prevent Gum Problems on Dental Implants Over a 6-month Period of Product Use
NCT07263698	PHASE3	COMPLETED	Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash
NCT07351370	PHASE3	COMPLETED	Effects of Two Daily CHX Mouthrinses on Plaque, Gingivitis and Staining
NCT02788786	PHASE2	COMPLETED	Feasibility and Acceptability of Use of Daily Oral Rinse in Pregnant Women in Rural Nepal
NCT03706781	PHASE1	COMPLETED	A Novel Mouthwash Formulation CTP/BNZ With Mucus Adhesive Polymer
NCT02297997	EARLY_PHASE1	COMPLETED	Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy
NCT02575235	EARLY_PHASE1	COMPLETED	Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia
NCT07490873	Not specified	RECRUITING	Antiplaque Efficacy and Patient Reported Outcome of Chlorohexidine, Cetylpyridinium Chloride, and Essential Oil Mouthwashes in Orthodontic Patients
NCT05270382	Not specified	COMPLETED	Effect of Mouthwashes on Oral Wound Healing and Microbiome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).